Lupin
LUPIN · Pharma > Pharmaceuticals & Drugs · Chairman: Manju D Gupta · MD: Nilesh Gupta · Listing date: Sept. 11, 2001 · Employees: 18573 · Mumbai · http://www.lupin.com

Stock Price vs Company Growth
1d
2.1%
1w
3.0%
1m
16.6%
3m
14.3%
6m
27.1%
1y
88.5%
5y
19.6%
10y
5.6%
all
17.5%

Use @ for users, # for companies and : for emojis
 
 
 
 
Last Traded Price

₹ 1,840 2.1%
1,487
1,850
Company Overview

Sales
20,011 Cr
Growth: 16.1%
Profit after Tax
1,914 Cr
Growth: 6.9%
Large Cap
83,886 Cr
P/E: 43.9x
Industry P/E: 37.3x
Fundamentals

Sales (Cr) ₹ 20,011
Growth 16.1%
EBITDA 19.0%
P/S 4.2x
Dividend 0.4%
P/E 43.9x
Book Value ₹ 313
PEG Ratio 2.7x
ROE 14.0%
P/B 5.9x
Shareholding Pattern

Institutions
Life Insurance Corporation Of India
6.99 %
Hdfc Trustee Company Limited-Hdfc Flexi Cap Fund
4.28 %
Government Pension Fund Global
1.21 %
Franklin India Focused Equity Fund
1.13 %
Icici Prudential Life Insurance Company Limited
1.13 %
Promoters
Lupin Investments Pvt Ltd
45.3 %
Manju D Gupta
0.85 %
Nilesh D Gupta
0.2 %
Anuja Gupta
0.16 %
Desh Bandhu Gupta Huf
0.14 %
Others
Rakesh Jhunjhunwala
1.6 %
Nps Trust - A/C Lic Pension Fund Sch-State Govt
1.48 %
Iepf
0.15 %
Increase    Decrease    No change
Company Profile Detailed

Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India.Products and services offered by the companyGlobal FormulationsActive Pharmaceuticals Ingredients (API)BiotechSpecialty BusinessOver The Counter (OTC)Global Manufacturing & Supply ChainAwards2007: Cardinal Health Conferred Two Awards - The ‘Trade Representative Of The Year’ And The ‘Quality Supplier Award’ To Lupin Pharmaceuticals Inc.
Investors (231)
Followers (55)